Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 296

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

Open access
Welsh, James, Menon, Hari, Chen, Dawei, Verma, Vivek, Tang, Chad, Altan, Mehmet, Hess, Kenneth, de Groot, Patricia, Nguyen, Quynh-Nhu, Varghese, Rejani, Comeaux, Nathan I, Simon, George, Skoulidis, Ferdinandos, Chang, Joe Y, Papdimitrakopoulou, Vasiliki, Lin, Steven H, Heymach, John V · 2020 · Journal for ImmunoTherapy of Cancer

Abstract

Background: In this phase I/II trial, we evaluated the safety and effectiveness of pembrolizumab, with or without concurrent radiotherapy (RT), for lung and liver lesions from metastatic non-small cell lung cancer (mNSCLC). Methods: Patients with lung or liver lesions amenable to RT plus at least one additional non-contiguous lesion were included regardless of programmed death-ligand 1 (PD-L1) status. Pembrolizumab was given at 200 mg every 3 weeks for up to 32 cycles with or without concurrent RT. Metastatic lesions were treated with stereotactic body RT (SBRT; 50 Gy in 4 fractions) if clinically feasible or with traditionally fractionated RT (45 Gy in 15 fractions) if not. The primary end point was the best out-of-field lesion response, and a key secondary end point was progression-free survival (PFS). Results: The median follow-up time was 20.4 months. One hundred patients (20 phase I, 80 phase II) were evaluable for toxicity, and 72 phase II patients were evaluable for treatment response. No patients in the phase I group experienced grade 4–5 events; in the phase II group, two had grade 4 events and nine had grade 3 events. The ORR in the combined-modality cohort (irrespective of RT schema) was 22%, vs 25% in the pembrolizumab group (irrespective of receipt of salvage RT) (p=0.99). In the concurrent pembrolizumab+RT groups, the out-of-field ORRs were 38% in the pembrolizumab+SBRT group and 10% in the pembrolizumab+traditional RT group. When examining the pembrolizumab-alone patients, the out-of-field ORRs were 33% in those designated to receive salvage SBRT (if required) and 17% for salvage traditional RT. In all patients, the median PFS for pembrolizumab alone was 5.1 months (95% CI 3.4 to 12.7 months), and pembrolizumab/RT (regardless of schema) was 9.1 months (95% CI 3.6 to 18.4 months) (p=0.52). An exploratory analysis revealed that for patients with low PD-L1 expression, the median PFS was 4.6 vs 20.8 months for pembrolizumab with and without RT, respectively (p=0.004). Conclusions: Concurrent immunoradiotherapy for mNSCLC is safe, although larger trials are required to address which patients benefit most from RT. Trial registration number: NCT02444741.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-001001

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 296

Metadata

Authors
Welsh, J., Menon, H., Chen, D., Verma, V., Tang, C., Altan, M., Hess, K., de Groot, P., Nguyen, Q.-N., Varghese, R., Comeaux, N. I., Simon, G., Skoulidis, F., Chang, J. Y., Papdimitrakopoulou, V., Lin, S. H., & Heymach, J. V.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-10
Volume
8
Issue
2
Pages
e001001
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3092159910
Cited by
296
References
17
FWCI
18.47
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. https://app.cochat.ai/papers/10.1136/jitc-2020-001001
The paper
Welsh, J., Menon, H., Chen, D., Verma, V., Tang, C., Altan, M., Hess, K., de Groot, P., Nguyen, Q.-N., Varghese, R., Comeaux, N. I., Simon, G., Skoulidis, F., Chang, J. Y., Papdimitrakopoulou, V., Lin, S. H., & Heymach, J. V. (2020). Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-001001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.